Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2020-10-20 Capital/Financing Update
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Tarsus Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933 for registering securities to be issued under employee benefit plans (Equity Incentive Plan, Employee Stock Purchase Plan, and Stock Plan). The document includes details about the securities to be registered, calculation of registration fees, incorporation by reference of other filings, indemnification provisions, and exhibits related to the plans. It is not a financial report, earnings release, or management discussion, but a capital market filing related to securities registration for employee stock plans. Form S-8 filings are specifically for registering securities under employee benefit plans and are classified as Capital/Financing Update filings in this taxonomy.
2020-10-20 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Tarsus Pharmaceuticals, Inc. It reports amendments to the company's Articles of Incorporation and Bylaws in connection with the closing of the company's IPO. The content focuses on corporate governance changes, such as the restated certificate of incorporation and bylaws, board structure, and shareholder rights. There are no financial statements or detailed financial performance data included. The document is not an annual or quarterly report, earnings release, or audit report. It is also not a proxy statement or voting results announcement. The primary focus is on corporate governance and structural changes to the company. Therefore, the most appropriate classification is Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related governance documents.
2020-10-20 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by Tarsus Pharmaceuticals, Inc. It includes extensive information typical of a registration statement or prospectus filed with the SEC, such as risk factors, use of proceeds, dividend policy, capitalization, dilution, selected financial data, management's discussion and analysis, business overview, management, executive compensation, principal stockholders, description of capital stock, underwriting, legal matters, and financial statements. The document is filed pursuant to Rule 424(b)(4), which relates to prospectus filings for securities offerings. This type of document is a capital markets filing related to fundraising and issuance of new shares to the public. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-10-16 English
Regulatory Filings 2020
Regulatory Filings
2020-10-16 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the offering, registration fee, and incorporation by reference to a prior registration statement. This is a capital markets filing related to fundraising and securities issuance, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive content about the offering, not just an announcement or certification.
2020-10-16 English
FORM 3 SUBMISSION
Director's Dealing
2020-10-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.